Proactive Investors - Run By Investors For Investors

Imugene presents positive new data validating its human cancer vaccine KEY-Vaxx

The Medical University Vienna and Imugene are working to develop mimotope based cancer vaccines.
cancer cells
Mimotopes are peptides that stimulate an immune response

Imugene Ltd (ASX:IMU) and Medical University Vienna have presented positive new data on the PD-1 mimotope cancer vaccine program at the American Association for Cancer Research (AACR) 2019 Annual Meeting.

The presentation by Dr Joshua Tobias from the Medical University Vienna was entitled ‘PD1 B cell mimotopes with functional PD1-PDL1 blocking capacity and anti-tumor activity: New strategy for a multi-level cancer immunotherapy.’

Imugene’s PD-1 B-cell vaccine, known as KEY-Vaxx, aims to induce the body to produce antibodies that block PD-1 signalling, and thus produce an anticancer effect.

The research led by Professor Ursula Wiedermann from the Medical University Vienna successfully inhibited tumor growth in a syngeneic mouse model of HER-2+ breast cancer via both passive and active immunisation strategies with PD-1 targeting B-cell cancer vaccines.

READ: Imugene gets development roadmap for cancer vaccine from FDA meeting

For the active immunisation study, which is of greatest interest and potential value to cancer researchers, the surrogate vaccine derived from mouse PD-1 was able to “brake tolerance” thereby inducing a sustained antibody response to the self-protein PD-1.

Importantly, the findings provide proof of concept and validation for Imugene’s human PD-1 cancer vaccine KEY-Vaxx.

View full IMU profile View Profile

Imugene Ltd Timeline

Related Articles

A stomach adenocarcinoma
February 13 2019
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.
genedrive device
May 23 2019
Here we take a closer look at Genedrive PLC (LON:GDR)
scientist in lab
February 26 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use